S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Stock market today: World shares mostly lower as Congress averts a US government shutdown
How is This "Hidden Gem" Thriving in a Turbulent Market? (Ad)
Bank of Japan survey shows manufacturers optimistic about economy
Sam Bankman-Fried must now convince a jury that the former crypto king was not a crook
How is This "Hidden Gem" Thriving in a Turbulent Market? (Ad)
New iPhones Hot In A Bad Way, But Apple Stock Chart is Bullish
Ride the Waves of Wealth With This Oil Tanker 17% Yield
Gold Could Be Heading for Record Highs - But How to Play It? (Ad)
Federal student loan payments are starting again. Here's what you need to know
Facing increasing pressure from customers, some miners are switching to renewable energy
S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Stock market today: World shares mostly lower as Congress averts a US government shutdown
How is This "Hidden Gem" Thriving in a Turbulent Market? (Ad)
Bank of Japan survey shows manufacturers optimistic about economy
Sam Bankman-Fried must now convince a jury that the former crypto king was not a crook
How is This "Hidden Gem" Thriving in a Turbulent Market? (Ad)
New iPhones Hot In A Bad Way, But Apple Stock Chart is Bullish
Ride the Waves of Wealth With This Oil Tanker 17% Yield
Gold Could Be Heading for Record Highs - But How to Play It? (Ad)
Federal student loan payments are starting again. Here's what you need to know
Facing increasing pressure from customers, some miners are switching to renewable energy
S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Stock market today: World shares mostly lower as Congress averts a US government shutdown
How is This "Hidden Gem" Thriving in a Turbulent Market? (Ad)
Bank of Japan survey shows manufacturers optimistic about economy
Sam Bankman-Fried must now convince a jury that the former crypto king was not a crook
How is This "Hidden Gem" Thriving in a Turbulent Market? (Ad)
New iPhones Hot In A Bad Way, But Apple Stock Chart is Bullish
Ride the Waves of Wealth With This Oil Tanker 17% Yield
Gold Could Be Heading for Record Highs - But How to Play It? (Ad)
Federal student loan payments are starting again. Here's what you need to know
Facing increasing pressure from customers, some miners are switching to renewable energy
S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Stock market today: World shares mostly lower as Congress averts a US government shutdown
How is This "Hidden Gem" Thriving in a Turbulent Market? (Ad)
Bank of Japan survey shows manufacturers optimistic about economy
Sam Bankman-Fried must now convince a jury that the former crypto king was not a crook
How is This "Hidden Gem" Thriving in a Turbulent Market? (Ad)
New iPhones Hot In A Bad Way, But Apple Stock Chart is Bullish
Ride the Waves of Wealth With This Oil Tanker 17% Yield
Gold Could Be Heading for Record Highs - But How to Play It? (Ad)
Federal student loan payments are starting again. Here's what you need to know
Facing increasing pressure from customers, some miners are switching to renewable energy
NASDAQ:BPTS

Biophytis (BPTS) Stock Forecast, Price & News

$1.24
-0.06 (-4.62%)
(As of 09/29/2023 08:52 PM ET)
Compare
Today's Range
$1.19
$1.29
50-Day Range
$0.92
$2.06
52-Week Range
$0.88
$9.02
Volume
98,600 shs
Average Volume
561,130 shs
Market Capitalization
$8.48 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$15.00

Biophytis MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
1,109.7% Upside
$15.00 Price Target
Short Interest
Healthy
0.97% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.67mentions of Biophytis in the last 14 days
Based on 10 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.09) to ($0.06) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.10 out of 5 stars


BPTS stock logo

About Biophytis (NASDAQ:BPTS) Stock

Biophytis S.A., a clinical-stage biotechnology company, focuses on the development of therapeutics that slow the degenerative processes and improve functional outcomes for patients suffering from age-related diseases. Its therapeutics focuses on targeting and activating key biological resilience pathways that could protect against and counteract the effects of the multiple biological and environmental stresses including inflammatory, oxidative, metabolic, and viral stresses that lead to age-related diseases. The company's lead drug candidate is Sarconeos (BIO101), an orally administered small molecule in development for the treatment of neuromuscular diseases, including sarcopenia and Duchenne muscular dystrophy (DMD), as well as in Phase 2/3 clinical study for the treatment of severe respiratory failure in patients suffering from COVID-19. It also develops Macuneos (BIO201), an orally administered small molecule for the treatment of retinal diseases, including dry age-related macular degeneration (AMD) and Stargardt disease. Biophytis SA has a collaboration agreement with AFM-Telethon for the development of its Sarconeos (BIO101) for the treatment of DMD. The company was incorporated in 2006 and is headquartered in Paris, France.

BPTS Price History

BPTS Stock News Headlines

Biophytis (BPTS) Soars 73% on Partnership With Skyepharma
How is This "Hidden Gem" Thriving in a Turbulent Market?
While Wall Street flounders and giants like Amazon & Microsoft lay off thousands... One overlooked company has been quietly achieving over 400% growth. How? By buying, building, and scaling a portfolio of promising brands in high-margin, recession-resistant verticals.
Why Biophytis (BPTS) Shares Are Sky-Rocketing
Biophytis Shares Surge 79% Following Covid-19 Partnership With Skyepharma
Why Is Biophytis (BPTS) Stock Up 49% Today?
How is This "Hidden Gem" Thriving in a Turbulent Market?
While Wall Street flounders and giants like Amazon & Microsoft lay off thousands... One overlooked company has been quietly achieving over 400% growth. How? By buying, building, and scaling a portfolio of promising brands in high-margin, recession-resistant verticals.
Why Are Biophytis Shares Skyrocketing Today?
See More Headlines
Receive BPTS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Biophytis and its competitors with MarketBeat's FREE daily newsletter.

BPTS Company Calendar

Today
10/02/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:BPTS
Fax
N/A
Employees
24
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$15.00
High Stock Price Forecast
$15.00
Low Stock Price Forecast
$15.00
Forecasted Upside/Downside
+1,109.7%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
($0.84) per share

Miscellaneous

Free Float
4,910,000
Market Cap
$6.32 million
Optionable
Not Optionable
Beta
1.03
7 Stocks to Buy And Hold Forever Cover

Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Key Executives

  • Mr. Stanislas Veillet Ph.D. (Age 58)
    Chairman & CEO
    Comp: $456.76k
  • Mr. Nicolas Fellmann (Age 55)
    Chief Financial Officer
  • Mr. Waly Dioh Ph.D. (Age 54)
    Chief Clinical Operating Officer
  • Dr. Pierre J. Dilda (Age 53)
    Chief Scientific Officer
  • Dr. Rene Lafont (Age 77)
    Scientific Advisor & Member of Scientific Advisory Board
  • Dr. Rob van Maanen FFPM (Age 53)
    M.B.A., M.D., Chief Medical Officer
  • Ms. _ Teylan
    Financial Controller













BPTS Stock - Frequently Asked Questions

Should I buy or sell Biophytis stock right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Biophytis in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" BPTS shares.
View BPTS analyst ratings
or view top-rated stocks.

What is Biophytis' stock price forecast for 2023?

1 brokerages have issued 1 year price objectives for Biophytis' stock. Their BPTS share price forecasts range from $15.00 to $15.00. On average, they predict the company's share price to reach $15.00 in the next year. This suggests a possible upside of 1,109.7% from the stock's current price.
View analysts price targets for BPTS
or view top-rated stocks among Wall Street analysts.

How have BPTS shares performed in 2023?

Biophytis' stock was trading at $3.9510 at the start of the year. Since then, BPTS stock has decreased by 68.6% and is now trading at $1.24.
View the best growth stocks for 2023 here
.

When did Biophytis' stock split?

Shares of Biophytis reverse split on Thursday, March 30th 2023. The 1-10 reverse split was announced on Thursday, March 30th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, March 30th 2023. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

When did Biophytis IPO?

(BPTS) raised $20 million in an IPO on Wednesday, February 10th 2021. The company issued 1,200,000 shares at $15.00-$18.00 per share. H.C. Wainwright acted as the underwriter for the IPO.

What is Biophytis' stock symbol?

Biophytis trades on the NASDAQ under the ticker symbol "BPTS."

How do I buy shares of Biophytis?

Shares of BPTS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Biophytis' stock price today?

One share of BPTS stock can currently be purchased for approximately $1.24.

How much money does Biophytis make?

Biophytis (NASDAQ:BPTS) has a market capitalization of $6.32 million.

How can I contact Biophytis?

Biophytis' mailing address is SORBONNE UNIVERSITY BC 9 BATIMENT A 4EME ETAGE 4 PLACE JUSSIEU, PARIS I0, 75252. The official website for the company is www.biophytis.com. The company can be reached via phone at 33-1-44-37-23-00.

This page (NASDAQ:BPTS) was last updated on 10/2/2023 by MarketBeat.com Staff

My Account -